Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Significant Drop in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the target of a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 45,388 shares, a drop of 18.6% from the February 12th total of 55,759 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 16,711 shares, the short-interest ratio is currently 2.7 days. Based on an average daily volume of 16,711 shares, the short-interest ratio is currently 2.7 days. Approximately 1.8% of the company’s shares are short sold.

Analysts Set New Price Targets

SLXN has been the topic of several analyst reports. Wall Street Zen downgraded Silexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Zacks Research upgraded Silexion Therapeutics to a “hold” rating in a research report on Tuesday, December 16th. Finally, Litchfield Hills Research began coverage on shares of Silexion Therapeutics in a research note on Monday, December 15th. They set a “buy” rating for the company. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $75.00.

Silexion Therapeutics Stock Down 3.7%

Shares of NASDAQ SLXN opened at $1.61 on Friday. Silexion Therapeutics has a 1 year low of $1.42 and a 1 year high of $22.36. The firm has a 50-day simple moving average of $1.85 and a two-hundred day simple moving average of $2.94. The company has a market cap of $5.02 million, a P/E ratio of -0.14 and a beta of -0.04. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.